Anzeige
Mehr »
Login
Samstag, 19.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C9EJ | ISIN: US45258H1068 | Ticker-Symbol:
NASDAQ
17.04.25
22:00 Uhr
1,670 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
IMMIX BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
IMMIX BIOPHARMA INC 5-Tage-Chart

Aktuelle News zur IMMIX BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
IMMIX BIOPHARMA Aktie jetzt für 0€ handeln
04.04.Immix Biopharma - All eyes on NEXICART-2283Immix's FY24 results summarize a period of focus on its lead CAR-T asset, NXC-201, which is being developed for amyloid light chain amyloidosis. Recent newsflow reflects heightened clinical activity...
► Artikel lesen
02.04.Artificial Intelligence Technology Solutions, Inc.: Immix and AITX's Robotic Assistance Devices (RAD) Announce Plans to Develop Strategic Integration to Advance Real-Time Incident Management with AI-Driven Automation398Las Vegas, Nevada--(Newsfile Corp. - April 2, 2025) - Immix®, the global provider of commercial central station and remote SOC software for managed video and security services, and Robotic Assistance...
► Artikel lesen
13.02.Immix Biopharma - NXC-201 receives FDA RMAT designation236Immix Biopharma has been granted a Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration (FDA) for the company's novel sterically optimized CAR-T treatment...
► Artikel lesen
10.02.Immix Biopharma, Inc.: Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis150FDA RMAT designation follows positive proof-of-concept U.S. clinical data from the NXC-201 NEXICART-2 clinical trial in relapsed/refractory AL AmyloidosisRMAT designation potentially streamlines the...
► Artikel lesen
15.01.Immix Biopharma - Shifting the ALA treatment paradigm with CAR-T340We review Immix Biopharma as it enters 2025, following the streamlining of its strategic priorities towards r/r ALA as the lead target indication for its CAR-T asset, NXC-201. The commencement of the...
► Artikel lesen
07.01.Immix Biopharma, Inc.: Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T314Successfully dosed 6 patients in safety run-in segment, now accelerating enrollmentPositive data from first four patients announced December 2024NXC-201 is the only one-time CAR-T therapy in development...
► Artikel lesen
19.12.24Immix Biopharma, Inc.: Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis175All four patients treated with NXC-201 normalized their disease markers within 30 days of dosing, of which, two are already classified as complete responders (CR), and the remaining two are bone marrow...
► Artikel lesen
16.12.24Immix Biopharma meldet vielversprechende Ergebnisse der CAR-T-Therapie3
16.12.24Immix Biopharma, Inc.: Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis163Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling clinical activity, rapid and deep complete...
► Artikel lesen
10.12.24Immix Biopharma reports strong CAR-T therapy results for AL Amyloidosis3
10.12.24Immix Biopharma, Inc.: Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 202414075% (12/16) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 4 lines of prior therapy in updated Phase 1/2 data as of December...
► Artikel lesen
25.11.24Immix Biopharma, Inc.: Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients2
12.11.24Immix Biopharma, Inc. - 10-Q, Quarterly Report2
04.10.24Immix Biopharma - US CAR-T trial progresses to dose expansion385Immix Biopharma's US-based NEXICART-2 trial continues to make steady progress through the clinic, with the company reporting that the trial has advanced to the dose expansion level of 450m cells, after...
► Artikel lesen
02.10.24Immix Biopharma, Inc.: Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2242Now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed Each of these two doses have produced complete responses...
► Artikel lesen
28.08.24Immix Biopharma, Inc.: Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2310New Sites Expand Opportunities for Patient Access and Enrollment Clinical Trial Sites Added Include Cleveland Clinic, UC Davis, and Sutter Health Lead site Memorial Sloan Kettering Cancer Center (MSKCC)...
► Artikel lesen
14.08.24Immix Biopharma - Full steam ahead with US CAR-T trial343Immix Biopharma's second quarter was headlined by intensified clinical activity for lead CAR-T asset NXC-201 (targeting amyloid light chain amyloidosis, ALA), followed by commencement of patient dosing...
► Artikel lesen
26.07.24Immix Biopharma, Inc.: California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)388LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us", "IMMX") (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell...
► Artikel lesen
10.07.24Immix Biopharma - US CAR-T trial commences patient dosing290Immix has announced that the first patient has been dosed in its Phase Ib NEXICART-2 trial of lead CAR-T asset NXC-201, which took place at lead study site, the Memorial Sloan Kettering Cancer Center....
► Artikel lesen
08.07.24Immix Biopharma, Inc.: Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201161Lead site Memorial Sloan Kettering Cancer Center (MSKCC)Timing of milestone in-line with mid-2024 guidanceData from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS...
► Artikel lesen
Seite:  Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1